Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OlaHsd mice—influence of treatment with the CRHR1-antagonist R121919/NBI 30775
Restricted accessOtherFirst published online January, 2009
Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OlaHsd mice—influence of treatment with the CRHR1-antagonist R121919/NBI 30775
Accumulating evidence suggests that corticotropin-releasing hormone (CRH) neurocircuitry modulate the neuroendocrine and behavioural phenotypes in depression and anxiety. Thus, the administration of the selective CRH-receptor 1 (CRHR1)—antagonist R121919/NBI 30775 has proven its ability to act as an anxiolytic in rats. It is still unclear whether vasopressinergic neuronal circuits, which are known to be involved in the regulation of emotionality, are affected by R121919/NBI 30775. Using DBA/2OlaHsd mice, we investigated the effects of chronic social defeat and concomitant treatment with R121919/NBI 30775 on 1) the behavioural profile in the modified hole board test and 2) in-situ hybridization analysis—based expression of arginine vasopressin (AVP) and CRH mRNA in both the hypothalamic paraventricular nucleus and supraoptic nucleus. The results suggest that chronic social defeat leads to increased avoidance behaviour and reduction in directed exploration, general exploration, and locomotion. Chronic treatment with the CRHR1-antagonist was effective in reversing the directed exploration to control level. The dissection of the antagonist-treated group into responders and non-responders using the parameter time spent on board revealed further positive effects of R121919/NBI 30775 on avoidance behaviour and locomotion. Behavioural changes were accompanied by alterations in AVP gene expression in the paraventricular nucleus. Taken together, the anxiolytic action of the CRHR1 antagonist was found in a subgroup of animals only, and further studies have to be done to clarify the inter-individual biological differences in response patterns to this compound to optimise its application under clinical conditions.
Aguilera, G., Rabadan-Diehl, C. (2000) Vasopressinergic regulation of the hypothalamic-pituitary- adrenal axis: implications for stress adaptation. Regul Pept96: 23-29.
2.
Antoni, FA (1993) Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol14: 76-122.
3.
Arborelius, L., Owens, MJ, Plotsky, PM, Nemeroff, CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol160: 1-12.
4.
Bhatnagar, S., Vining, C., Iyer, V., Kinni, V. (2006) Changes in hypothalamic-pituitary-adrenal function, body temperature, body weight and food intake with repeated social stress exposure in rats. J Neuroendocrinol18: 13-24.
5.
Bjorkqvist, K. (2001) Social defeat as a stressor in humans. Physiol Behav73: 435-442.
6.
Blanchard, RJ, McKittrick, CR, Blanchard, DC (2001) Animal models of social stress: Effects on behavior and brain neurochemical systems. Physiol Behav73: 261-271.
7.
Caspi, A., Sugden, K., Moffitt, TE, Taylor, A., Craig, IW, Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., Poulton, R. (2003) Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science301: 386-389.
8.
Chaouloff, F., Durand, M., Mormede, P. (1997) Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/ dark and dark/light tests. Behav Brain Res85: 27-35.
9.
Chen, C., Grigoriadis, DE (2005) NBI 30775 (R121919), an orally active antagonist of the corticotropin-releasing factor (CRF) type-1 receptor for the treatment of anxiety and depression. Drug Dev Res65: 216-226.
10.
Chen, C., Wilcoxen, KM, Huang, CQ, Xie, YF, McCarthy, JR, Webb, TR, Zhu, YF, Saunders, J., Liu, XJ, Chen, TK, Bozigian, H., Grigoriadis, DE (2004) Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazol o[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J Med Chem47: 4787-4798.
11.
de Kloet, ER, Joels, M., Holsboer, F. (2005) Stress and the brain: From adaptation to disease . Nat Rev Neurosci6: 463-475.
12.
Ebner, K., Wotjak, CT, Landgraf, R., Engelmann, M. (2002) Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats. Eur J Neurosci15: 384-388.
13.
Engelmann, M., Wotjak, CT, Neumann, I., Ludwig, M., Landgraf, R. (1996) Behavioral consequences of intracerebral vasopressin and oxytocin: Focus on learning and memory. Neurosci Biobehav Rev20: 341-358.
14.
Erhardt, A., Ising, M., Unschuld, PG, Kern, N., Lucae, S., Putz, B., Uhr, M., Binder, EB, Holsboer, F., Keck, ME (2006) Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology31: 2515-2522.
15.
Gutman, DA, Owens, MJ, Skelton, KH, Thrivikraman, KV, Nemeroff, CB (2003) The corticotropin-releasing factor(1) receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress . J Pharmacol Exp Ther304: 874-880.
16.
Heinrichs, SC, De Souza, EB, Schulteis, G., Lapsansky, JL, Grigoriadis, DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology27: 194-202.
17.
Held, K., Kunzel, H., Ising, M., Schmid, DA, Zobel, A., Murck, H., Holsboer, F., Steiger, A. (2004) Treatment with the C RH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res38: 129-136.
18.
Holsboer, F. (2000) The corticosteroid receptor hypothesis of depression . Neuropsychopharmacology23: 477-501.
19.
Holsboer, F. (2001) Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord62: 77-91.
20.
Holsboer, F. (2003) High-quality antidepressant discovery by understanding stress hormone physiology. Ann N Y Acad Sci1007: 394-404.
21.
Jaccard, J., Becker, MA, Wood, G. (1984) Pairwise Multiple Comparison Procedures - a Review . Psychol Bull96: 589-596.
22.
Keck, ME, Ohl, F., Holsboer, F., Muller, MB (2005) Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neurosci Biobehav Rev29: 867-889.
23.
Keck, ME, Welt, T., Muller, MB, Landgraf, R., Holsboer, F. (2003a) The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry36: 27-31.
24.
Keck, ME, Welt, T., Muller, MB, Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., Landgraf, R. (2003b) Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology28: 235-243.
25.
Keck, ME, Welt, T., Wigger, A., Renner, U., Engelmann, M., Holsboer, F., Landgraf, R. (2001) The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci13: 373-380.
26.
Keeney, A., Jessop, DS, Harbuz, MS, Marsden, CA, Hogg, S., Blackburn-Munro, RE (2006) Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice. J Neuroendocrinol18: 330-338.
27.
Kendler, KS, Kuhn, JW, Vittum, J., Prescott, CA, Riley, B. (2005) The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression - A replication. Arch Gen Psychiatry62: 529-535.
28.
Kuenzel, HE, Zobel, AW, Nickel, T., Ackl, N., Uhr, M., Ising, M., Sonntag, A., Holsboer, F. (2001) Treatment with the CRH-1-receptor antagonist R121919 shows a high safety in the HPA system and clinical routine. Biol Psychiatry49: 51S-51S.
29.
Martin, P. (1998) Animal models sensitive to anti-anxiety agents . Acta Psychiatr Scand98: 74-80.
30.
Martinez, M., Calvo-Torrent, A., Pico-Alfonso, MA (1998) Social defeat and subordination as models of social stress in laboratory rodents: A review. Aggress Behav24: 241-256.
31.
Merali, Z., Kent, P., Du, LS, Hrdina, P., Palkovits, M., Faludi, G., Poulter, MO, Bedard, T., Anisman, H. (2006) Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol Psychiatry59: 594-602.
32.
Muller, MB, Zimmermann, S., Sillaber, I., Hagemeyer, TP, Deussing, JM, Timpl, P., Kormann, MSD, Droste, SK, Kuhn, R., Reul, J., Holsboer, F., Wurst, W. (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci6: 1100-1107.
33.
Nakase, S., Kitayama, I., Soya, H., Hamanaka, K., Nomura, J. (1998) Increased expression of magnocellular arginine vasopressin mRNA in paraventricular nucleus of stress-induced depression-model rats. Life Sci63: 23-31.
34.
Nemeroff, CB, Vale, WW (2005) The neurobiology of depression: Inroads to treatment and new drug discovery. J Clin Psychiatry66: 5-13.
35.
Nestler, EJ, Barrot, M., DiLeone, RJ, Eisch, AJ, Gold, SJ, Monteggia, LM (2002) Neurobiology of depression. Neuron34: 13-25.
36.
Ohl, F. (2003) Testing for anxiety. Clin Neurosci Res3: 233-238.
37.
Ohl, F., Holsboer, F., Landgraf, R. (2001a) The modified hole board as a differential screen for behavior in rodents. Behav Res Methods Instrum Comput33: 392-397.
38.
Ohl, F., Roedel, A., Binder, E., Holsboer, F. (2003) Impact of high and low anxiety on cognitive performance in a modified hole board test in C57BL/6 and DBA/2 mice. Eur J Neurosci17: 128-136.
39.
Ohl, F., Toschi, N., Wigger, A., Henniger, MSH, Landgraf, R. (2001b) Dimensions of emotionality in a rat model of innate anxiety. Behav Neurosci115: 429-436.
40.
Pariante, CM, Miller, AH (2001) Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry49: 391-404.
41.
Post, A., Ohl, F., Almeida, OFX, Binder, EB, Rucker, M., Welt, S., Binder, E., Holsboer, F., Sillaber, I. (2005) Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Psychopharmacology180: 150-158.
42.
Raadsheer, FC, Hoogendijk, WJG, Stam, FC, Tilders, FJH, Swaab, DF (1994) Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed-Patients . Neuroendocrinology60: 436-444.
43.
Schmidt, M., Oitzl, MS, Muller, MB, Ohl, F., Wurst, W., Holsboer, F., Levine, S., De Kloet, ER (2003) Regulation of the developing hypothalamic-pituitary-adrenal axis in corticotropin releasing hormone receptor 1-deficient mice. Neuroscience119: 589-595.
Welt, T., Engelmann, M., Renner, U., Erhardt, A., Muller, MB, Landgraf, R., Holsboer, F., Keck, ME (2006) Temazepam triggers the release of vasopressin into the rat hypothalamic paraventricular nucleus: Novel insight into benzodiazepine action on hypothalamic-pituitary-adrenocortical system activity during stress . Neuropsychopharmacology31: 2573-2579.
46.
Zobel, AW, Nickel, T., Kunzel, HE, Ackl, N., Sonntag, A., Ising, M., Holsboer, F. (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res34: 171-181.
